SL Science Holding Ltd(SLBT)

Biotechnology · Taipei, NY

$1.52-0.07 (-4.40%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T21:23:22.827Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:23:22.827Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 852,354,826
Total debt · period ending 2025-12-31: 213,405
Cash · period ending 2025-12-31: 1,258,616
TTM operating income: N/A

FMP input reference: 680db3c2305e98602fe5277f15244516f30a0ab53cbf5830e5b41f5092839f7c

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

SLBT EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

SLBT Competitors' EV/EBIT Ratio

SLBT

SL Science Holding Ltd

Current

Market Cap

$852.35M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RIGL

Rigel Pharmaceuticals, Inc.

vs SLBT

Market Cap

$853.13M

EV/EBIT Ratio

9.56x

TTM Avg

6.42x

3Y Avg

12.92x

5Y Avg

12.92x

ALMS

Alumis Inc.

vs SLBT

Market Cap

$855.38M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

QDEL

QuidelOrtho Corporation

vs SLBT

Market Cap

$857.16M

EV/EBIT Ratio

N/A

TTM Avg

33.92x

3Y Avg

15.14x

5Y Avg

22.68x

PACB

Pacific Biosciences of California, Inc.

vs SLBT

Market Cap

$838.62M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BBNX

Beta Bionics, Inc.

vs SLBT

Market Cap

$838.16M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SIBN

SI-BONE, Inc.

vs SLBT

Market Cap

$867.03M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ODTX

Odyssey Therapeutics, Inc.

vs SLBT

Market Cap

$870.81M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GLUE

Monte Rosa Therapeutics, Inc.

vs SLBT

Market Cap

$833.81M

EV/EBIT Ratio

N/A

TTM Avg

76.83x

3Y Avg

76.83x

5Y Avg

76.83x

SGP

SpyGlass Pharma, Inc. Common Stock

vs SLBT

Market Cap

$828.48M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
SL Science Holding Ltd (SLBT)	$852.35M	N/A	N/A	N/A	N/A
Rigel Pharmaceuticals, Inc. (RIGL)vs ›	$853.13M	9.56x	6.42x	12.92x	12.92x
Alumis Inc. (ALMS)vs ›	$855.38M	N/A	N/A	N/A	N/A
QuidelOrtho Corporation (QDEL)vs ›	$857.16M	N/A	33.92x	15.14x	22.68x
Pacific Biosciences of California, Inc. (PACB)vs ›	$838.62M	N/A	N/A	N/A	N/A
Beta Bionics, Inc. (BBNX)vs ›	$838.16M	N/A	N/A	N/A	N/A
SI-BONE, Inc. (SIBN)vs ›	$867.03M	N/A	N/A	N/A	N/A
Odyssey Therapeutics, Inc. (ODTX)vs ›	$870.81M	N/A	N/A	N/A	N/A
Monte Rosa Therapeutics, Inc. (GLUE)vs ›	$833.81M	N/A	76.83x	76.83x	76.83x
SpyGlass Pharma, Inc. Common Stock (SGP)vs ›	$828.48M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

SLBT EV/EBIT Ratio Metrics

SLBT Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics